MC
Therapeutic Areas
Inmunova Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INM004 | Hemolytic uremic syndrome (Shiga toxin‑producing E. coli) | Phase 3 |
Leadership Team at Inmunova
MC
Mariana Colonna
Head of Clinical Research and Regulatory Affairs
CL
Candelaria Lamas
Head of Administration and Finance
VZ
Vanesa Zylberman
Head of R&D and Technical Director
SS
Santiago Sanguineti
Chief Operating Officer
LS
Linus Spatz
Founding Partner and Chief Executive Officer
FG
Fernando Goldbaum
Founding Partner and Scientific Advisor